Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis
Economic impact of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis on families
1 evidence topic · 1 source
Informal and professional caregiver costs by fibrosis stage in adults with NASH, United States and five European countries, GAIN study
“The secondary objective was to estimate the total annualised cost of the disease, including all health-related items and non-health and indirect costs accrued by patients and their families.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall direct non-medical cost per patient was €4,917 (Table 5). Professional (34%) and informal (48%) caregivers accounted for most of these costs and these percentages increased with disease severity (fibrosis stage).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers, whether professional or informal, accounted for the greatest proportion of direct non-medical costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The remaining direct non-medical costs resulted from transport, disability allowances, alternative therapies, home alteration, and OTC remedies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Mean annual direct non-medical cost per patient (SD), patient-reported | Early fibrosis (n = 546) | Advanced fibrosis (n = 221) | USA (n = 97) |
|---|---|---|---|
| Non-medical | “€1,704 (5,785)”View highlighted excerpt for this quote | “€4,661 (9,839)”View highlighted excerpt for this quote | “€3,243 (7,685)”View highlighted excerpt for this quote |